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ABSTRACT
Background: In type 2 diabetes mellitus
(T2DM), progressive loss of beta cell function
over time requires treatment intensification and
eventually initiation of insulin for many
patients. Relative to metformin, a greater rate
of decline in beta cell function over time has
been observed with sulfonylurea treatment.
The present study examined the association
between initial monotherapy with metformin
or sulfonylurea and subsequent initiation of
insulin in older subjects with T2DM.
Methods: In a retrospective cohort study using
the GE electronic medical record database,
eligible subjects with T2DM included those
C65 years who received their first prescription
of sulfonylurea or metformin as initial
monotherapy between January 1, 2003 to
December 31, 2008. The follow-up period
lasted to the end of 2009 or the subject’s latest
data available. Insulin initiation was determined
by prescription records. Logistic regression
analysis evaluated the likelihood of insulin
addition. A Cox regression model estimated
time to initiation of insulin. Differences in
baseline characteristics were controlled for
using propensity score matching.
Results: Overall, 12,036 subjects were
included in the analysis. Mean age was
75 years and 50% were male. Subjects who
initiated with sulfonylurea had a significantly
(P\0.001) higher incidence of insulin
addition (2.8% vs. 1.4%) compared to those
initiated with metformin within 1 year of
follow-up. The likelihood of initiating insulin
was higher in subjects initiated with
sulfonylurea than with metformin (adjusted
odds ratio 1.82, 95% confidence interval [CI]
1.40–2.38; P\0.001). Sulfonylurea use was
also significantly associated with a shorter
time to insulin use compared to metformin
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(adjusted hazards ratio 2.10, 95% CI 1.83–2.39;
P\0.001).
Conclusion: In a cohort of older subjects with
T2DM initiating antihyperglycemic therapy,
new users of sulfonylurea monotherapy were
more likely to receive insulin therapy and
received it earlier than those starting with
metformin.
Keywords: Elderly; Insulin therapy; Metformin;
Sulfonylurea; Type 2 diabetes
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is characterized
by hyperglycemia related to a progressive loss of
beta cell function [1]. The selection of initial
antihyperglycemic therapy influences treatment
failure and the need for additional therapy in
individuals with T2DM [2]. Metformin and
sulfonylureas are the two most commonly
prescribed oral antihyperglycemic agents for
initial therapy for T2DM because of their well-
defined clinical profiles and cost [3]. These
agents work by distinct mechanisms, with
metformin primarily reducing hepatic glucose
production and insulin resistance, and
sulfonylureas stimulating insulin release by
binding to their receptor on the pancreatic
beta cell. In recently diagnosed patients with
T2DM, monotherapy treatment with the
sulfonylurea, glyburide, was associated with an
increased likelihood of treatment failure
compared with metformin (and rosiglitazone)
over 4 years [4]. Despite a larger initial (within
6 months) increase in beta cell function with
glyburide, greater treatment failure with
glyburide was related to a greater decline in
beta cell function overall relative to metformin
(and rosiglitazone) [4, 5].
Beta cell function also declines with aging [6].
In older individuals with T2DM, sulfonylurea
use tends to increase and metformin use
declines [7–9]. Given the greater loss of beta
cell function over time with sulfonylureas and
the reduced beta cell function associated with
aging, the present retrospective observational
study was performed to examine the influence
of initial monotherapy with metformin or a
sulfonylurea on the subsequent use of insulin
therapy in older subjects with T2DM.
Observational studies are used to estimate
treatment effects when randomized controlled
trials are not feasible. However, the lack of
randomization may lead to imbalances in
subject characteristics due to channeling bias
[10]. Differences in baseline characteristics must
be adjusted for in order to minimize channeling
bias and determine treatment effect. Propensity
score matching is a statistical technique used to
generate well-defined cohorts matched on
specific baseline characteristics in order to
control for potential confounding [11].
Therefore, the present analysis used propensity
score matching to generate two well-matched
cohorts of older subjects initially treated with
metformin or a sulfonylurea.
METHODS
Study Design and Subject Selection
Data for this retrospective cohort study of US
subjects were obtained using GE Healthcare’s
Clinical Data Services electronic medical record
database. For the index period of January 1, 2003
to December 31, 2008, subjects with newly or
previously diagnosed T2DM were included in the
analysis if they were at least 65 years of age,
received their first prescription for metformin or
sulfonylurea as monotherapy during the index
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period, and continued monotherapy for at
least 90 days following the index date (i.e.,
date of first prescription, Fig. 1). Subjects
also had to have no prescriptions for any
antihyperglycemic agents within the 1-year
period prior to the index date, and were
required to be continually enrolled in the
database for at least 1 year before the index
date (i.e., baseline data), and to have at least
1 year of follow-up data. The follow-up period
was censored at the end of 2009 or the date of
the subjects’ latest available data.
The 1-year period before the index date
was used to ensure adequate time to capture
baseline characteristics on all subjects. Baseline
variables included the following measurements:
age, gender, body mass index, blood pressure,
and laboratory measurements (glycated
hemoglobin [HbA1c], total cholesterol, low-
density lipoprotein cholesterol, high-density
lipoprotein cholesterol, triglycerides, serum
creatinine, and liver enzymes). History of
cardiovascular conditions, microvascular
complications, renal and liver disease, and
smoking were collected in the baseline period.
Due to the nature of the database and
limited baseline collection period used, the
duration of diabetes was not assessed. The
presence of T2DM and baseline history of
cardiovascular or microvasculature events were
identified in the database using the
International Classification of Diseases, Ninth
revision diagnosis/procedure and Current
Procedural Terminology codes.
Outcomes
The proportion of subjects initiating insulin
therapy during the 1-year follow-up period was
the primary outcome of interest. Factors
influencing the likelihood of or time to
initiating insulin therapy were also evaluated.
The time from initial oral monotherapy with
metformin or sulfonylurea to insulin initiation
was estimated based on prescription records.
Additional analyses extended the follow-up
period to 2 or 3 years.
Statistical Analysis
To control for confounding, propensity score
matching was used to generate matched cohorts
of subjects treated with metformin or
sulfonylurea monotherapy and at least 1 year of
follow-up data. A multivariate logistic regression
model was constructed first to calculate the
propensity score, defined as the conditional
probability of initiating sulfonylurea versus
metformin monotherapy as a function of all
measured baseline factors described above. A
one-to-one greedy matching algorithm was
employed as the next step to match propensity
scores of the two treatment cohorts from best to
next best [12]. Best matches were defined as pairs
Fig. 1 Study design
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with the highest digit match (0.00001) on
propensity score. The matching algorithm
proceeded sequentially to the next highest digit
match. No more matches can be made below the
lowest allowable digit 0.1.
Data are presented as the mean or proportion
for each treatment group (metformin or
sulfonylurea). To confirm adequate matching,
between-group differences in the baseline
characteristics were assessed with t tests for
continuous variables and v2 tests for categorical
variables. Significance was assessed at P\0.05.
Logistic regression analyses were used to
estimate the odds ratio (OR) associated with
the likelihood of initiating insulin therapy
within the fixed follow-up period. A Cox
proportional hazards regression model was
used to estimate the time to insulin initiation.
The regression analyses were adjusted for
baseline characteristics. Additional analyses
were based on matched cohorts with at least 2
or 3 years of follow-up data.
RESULTS
Of the 20,764 older subjects with T2DM who
received their first prescription with metformin
or sulfonylurea and had at least 1 year of follow-up
data, matched cohorts of 6,018 subjects per
treatment were generated using propensity score
matching (Table 1). Baseline demographics,
laboratory measures, and comorbid conditions
for these well-matched cohorts are shown in
Table 2. Briefly, these subjects (50% male) had a
mean age of 75 years, mean body mass index of
31 kg/m2, and mean HbA1c of 7.2% (Table 2).
The proportion of subjects initiating insulin
within 1 year was significantly higher (2.8% vs.
1.4%; P\0.001) with sulfonylurea compared to
metformin (Fig. 2). After adjusting for baseline
characteristics, the likelihood of initiating
insulin therapy within 1 year of follow-up was
higher in subjects who started with sulfonylurea
monotherapy than with metformin (adjusted
OR 1.82, 95% confidence interval [CI] 1.40–2.38;
P\0.001). Higher HbA1c and elevated serum
creatinine were also associated with initiating
insulin therapy (Table 3). Male gender was
associated with a lower likelihood of initiating
insulin therapy. Sulfonylurea use was also
associated with a shorter time to initiating
insulin therapy compared to metformin
(adjusted hazards ratio 2.10, 95% CI 1.83–2.39;
P\0.001) (Table 4). Higher HbA1c and elevated
serum creatinine were associated with a shorter
time to initiating insulin therapy (Table 4).
Table 1 Subject accrual
Group description Subject
counts
All subjects with type 2 diabetes C65 years old identiﬁed in the database between 2002 and 2009 204,756
Subjects received ﬁrst prescription for antihyperglycemic therapy between 2003 and 2008 137,023
Subjects with at least 12 months of recorded history prior to and after the ﬁrst prescription 41,879
Subjects received ﬁrst prescription for metformin or sulfonylurea monotherapy 20,764
Subjects received ﬁrst prescription for metformin or sulfonylurea monotherapy
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In an analysis using matched cohorts with at
least 2 years of follow-up data (n = 4,691 per
treatment), significantly more subjects initiated
with sulfonylurea therapy started insulin
therapy compared to those initiated with
metformin (Fig. 2). After adjusting for baseline
characteristics for this cohort, the likelihood of
initiating insulin therapy within 2 years of
follow-up was higher in subjects initiated with
sulfonylurea than with metformin (adjusted OR
2.27, 95% CI 1.82–2.82; P\0.001).
Similar results were identified for a matched
cohorts with at least 3 years of follow-up data
(n = 3,312 per treatment). Significantly more
subjects initiated with sulfonylurea therapy
started insulin therapy compared to those
initiated with metformin (Fig. 2). After
adjusting for baseline characteristics for this
cohort, the likelihood of initiating insulin
therapy within 3 years of follow-up was also
higher in subjects initiated with sulfonylurea
than with metformin (adjusted OR 1.98, 95% CI
1.59–2.45; P\0.001).
DISCUSSION
The present study evaluated the effect of initial
treatment with metformin or sulfonylurea
monotherapy on subsequent treatment
intensification with insulin therapy in US
subjects with T2DM and aged C65 years. Older
adults with T2DM were examined because older
age is associated with reduced beta cell function
Table 2 Baseline characteristics with propensity score
matching for those initiating monotherapy of metformin






Age, years 75.2 75.4 0.11
Males, % 50.2 49.3 0.33
Body mass index, kg/m2 31.1 31.0 0.36
Smoking status (yes), % 5.3 4.8 0.17
HbA1c, % 7.2 7.2 0.85
Total cholesterol, mg/dL 180.6 180.6 0.96
LDL-cholesterol, mg/dL 100.6 101.0 0.68
HDL-cholesterol, mg/dL 46.1 46.4 0.35
Triglycerides, mg/dL 177.9 181.4 0.15




Serum creatinine, mg/dL 1.08 1.08 0.20




Cardiovascular conditions, % 9.1 8.9 0.63
Stroke, % 1.1 0.9 0.46
Transient ischemic attack, % 0.6 0.6 0.63








Retinopathy/blindness, % 0.5 0.4 0.43
Neuropathy/neuropathy, % 3.6 3.7 0.70




Liver disease, % 0.4 0.5 0.73
HbA1c glycated hemoglobin, HDL high-density lipoprotein, LDL low-
density lipoprotein
Fig. 2 Proportion of subjects who initiated insulin within
1, 2, or 3 years after starting monotherapy with metformin
or sulfonylurea (see text for number of subjects per
treatment group at each time point)
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[6]. Thus, any treatments with negative
effects on beta cell function may increase
the requirement for insulin therapy in this
population. Comparisons between treatments
may be confounded by channeling bias and the
present study attempts to control for this by
using propensity score matching [10]. In the
present study in two well-matched groups of
older subjects, approximately twice as many
subjects initiated insulin therapy within 1, 2, or
3 years of receiving their first prescription for
sulfonylurea monotherapy compared with
metformin monotherapy. The annualized rates
of insulin initiation were approximately 1.5%
for those started with metformin and 3% for
those started with sulfonylureas. These rates on
insulin initiation are generally similar to the
annualized rates reported for a Canadian (1%)
and a Swedish cohort (3.5%) of patients
who initiated therapy with an oral
antihyperglycemic agent [13, 14]. Furthermore,
initiating treatment with sulfonylurea
monotherapy was significantly associated with
a shorter time to insulin use compared to
initiating with metformin monotherapy.
The present results in US subjects are
generally consistent with those in cohort
studies from other countries. In a cohort of
older Canadian subjects with T2DM
(age C 66 years), new users of insulin
secretagogues (including sulfonylureas) were
more likely to initiate insulin therapy than new
users of metformin [13]. In a Swedish cohort of
subjects with T2DM, initial metformin
monotherapy use was associated with a lower
probability of initiating insulin relative to non-
metformin therapy (primarily sulfonylurea) [14].
In a German cohort, treatment with a
sulfonylurea was associated with a higher
probability of initiating insulin therapy
compared with metformin [15]. Furthermore,
initial monotherapy with sulfonylurea led to
more subsequent use of insulin relative to
metformin use in cohorts from Scotland [16]
and Canada [17]. Although these studies did not
specifically match cohorts of initial metformin
and sulfonylurea users for baseline
characteristics, it is apparent that sulfonylurea
use relative to metformin is an important factor
contributing to the initiation of insulin therapy.
Table 3 Adjusted OR for insulin initiation in the cohort with 1 year of follow-up data
Baseline variables OR 95% CI P value
Sulfonylurea vs. metformin (metformin = reference) 1.82 1.40–2.38 \0.001
Age at ﬁrst prescription, years 0.97 0.94–1.00 0.022
Male gender 0.66 0.50–0.86 0.003
HbA1c\8% (reference)
HbA1c C 8% and\9% 2.16 1.56–2.99 \0.001
HbA1c C 9% 2.03 1.34–3.06 0.001
Total cholesterol, mg/dL 0.996 0.993–0.999 0.013
Serum creatinine, mg/dL 1.92 1.30–2.84 0.001
Alanine aminotransferase, U/L 0.991 0.982–0.999 0.035
Nonsigniﬁcant variables included in the analysis: body mass index, smoking status, blood pressure, cardiovascular conditions,
microvascular complications, chronic renal disease, and liver disease
CI conﬁdence interval, HbA1c glycated hemoglobin, OR odds ratio
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Secondary failure occurs with all types of
antihyperglycemic treatments [2, 4, 18].
Secondary failure with sulfonylureas has been
associated with desensitization of insulin
secretion to prolonged exposure to
sulfonylureas [19] and sulfonylurea-induced
apoptosis of the beta cell [20–22]. Conversely,
metformin reduces hepatic glucose output and
increases insulin sensitivity; thus potentially
reducing the burden on the beta cell to secrete
insulin. The results of the present study suggest
that selecting a treatment that is not associated
with negative effects on an underlying
pathophysiology of T2DM (i.e., declining beta
cell function) prolongs the time from treatment
initiation to intensification with insulin therapy.
The difference may even be greater depending on
the type of sulfonylurea, as there are differences
in secondary failure within this class [23].
Baseline factors were also associated with
initiating insulin therapy, including worse
glycemic control and elevated serum creatinine.
Higher HbA1c was a significant factor leading to
insulin initiation in other cohort studies [14–16].
These factors may have precipitated more office
visits and, hence, more opportunity for physicians
to intensify or alter antihyperglycemic treatment
with insulin.
There are several strengths and limitations
related to this analysis. With regard to strengths,
the study included large, well-matched cohorts
of [6,000 subjects per treatment with at least
1 year of follow-up data. Similar findings in
matched cohorts with 2 or 3 years of follow-up
data also lend support to the robustness of the
present findings. However, the following
limitations need to be considered when
interpreting the present results. This was a
retrospective study and subjects were not
randomly assigned to initial treatments.
Although propensity score matching generated
well-matched cohorts, additional factors that
were not available from the data and, thus, were
not accounted for (e.g., measures of on-
treatment glycemic control, duration of
diabetes) may have influenced the results.
Subjects were only required to be on
monotherapy for 90 days for inclusion in the
analysis population, and subsequent
discontinuation or switching of initial therapy
or prescriptions for additional oral
antihyperglycemic therapies were not accounted
for in this analysis. This approach is similar-to-
intent to treat within clinical trial studies. Finally,
changes in treatment paradigms for T2DM and
the availability of additional antihyperglycemic
Table 4 Cox proportional hazards model for time to add-on insulin use in the cohort with 1 year of follow-up data
Baseline variable HR 95% CI P value
Sulfonylurea vs. metformin (metformin = reference) 2.10 1.83–2.39 \0.001
Age at ﬁrst prescription, years 0.98 0.97–0.99 0.002
Body mass index, kg/m2 1.011 1.001–1.021 0.036
HbA1c\8% (reference)
HbA1c C 8% and\9% 1.65 1.39–1.96 \0.001
HbA1c C 9% 1.61 1.32–1.98 \0.001
Serum creatinine, mg/dL 1.69 1.37–2.07 \0.001
Nonsigniﬁcant variables included in the analysis: gender, smoking status, total cholesterol, blood pressure, cardiovascular
conditions, microvascular complications, chronic renal disease, and liver disease
CI conﬁdence interval, HbA1c glycated hemoglobin, HR hazard ratio
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therapies over time may have contributed to the
differences between groups.
CONCLUSION
In a US cohort of older subjects with T2DM
initiating antihyperglycemic therapy, new users
of sulfonylurea monotherapy were more likely
to receive insulin therapy and received it earlier
than those who started with metformin
monotherapy.
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